Recently a novel oncogene, PTTG (pituitary tumor transforming gene) was isolated from a rat pituitary tumor cell line whose expression is apparently correlated with pituitary tumorigenesis. In the rat, estradiol (E 2 ) is known to induce anterior pituitary hyperplasia. The effects of E 2 , however, vary greatly among rat strains. Therefore we examined the expression of PTTG and its regulation by E 2 in F344, Wistar, Brown-Norway and Donryu rats. Four-week-old females were ovariectomized and a pellet containing 10 mg of E 2 was given s.c. Total RNA was isolated from the pituitary gland and PTTG mRNA was measured with a competitive RT-PCR technique. The F344 strain was the most susceptible to E 2 induction of pituitary tumorigenesis, followed by Wistar and BrownNorway, while no increase in pituitary weight was noted in Donryu rats. PTTG mRNA in the gland was induced by E 2 within 48-72 h in F344 and Wistar, but not in Brown-Norway or Donryu strains. These data suggest that PTTG expression may at least in part be responsible for strain differences in E 2 -induced pituitary tumorigenesis.
The oncogene PTTG (pituitary tumor transforming gene) was first isolated from rat GH (growth hormone) tumor cell lines by differential mRNA display. 1) Induction of PTTG alone results in transformation in NIH 3T3 cells, which become tumorigenic in vivo. Human PTTG was found to be expressed at only low levels in normal pituitary tissues but highly in secreting and non-secreting pituitary tumors as well as in a variety of tumor cell lines, including lung carcinoma, melanoma, leukemia, lymphoma and HeLa examples. [2] [3] [4] More recent investigations have revealed that the gene is identical to securin, a sister chromatid separation inhibitor, whose overexpression may have an impact on cancer development by increasing genetic instability. 5) Chronic treatment of rats with estradiol (E 2 ) is known to result in the development of anterior pituitary tumors, which are initially benign masses and hormone-dependent, but may subsequently become autonomous. A study with F344 rats showed that PTTG mRNA in the pituitary gland increases in this process and that E 2 may regulate the expression. 6) However, susceptibility to E 2 induction of pituitary tumors is highly strain-dependent. 7, 8) The F344 strain is the most widely studied and the most sensitive to estrogen. Other rat strains including ACI, Wistar-Furth and Copenhagen have been reported to display estrogendependent growth and tumor induction. [9] [10] [11] On the other hand, the Brown-Norway, Holtzman and Sprague Dawley strains appear to be insensitive or resistant. 7, 12) When susceptible strains were treated with E 2 , the size of the pituitary gland started to increase immediately and steadily expanded without any evident focal growth. 9) The designation of tumor is given on the basis of the size of the gland and the abnormal appearance of the cells, which are highly correlated. 13) Thus, the E 2 -induced weight increase in the gland well represents the E 2 -dependent tumorigenicity. The hypothalamus is not essential for the E 2 stimulation of pituitary growth, based on experiments involving transplantation of the pituitary gland. 14) Several investigations have indicated the contribution of multiple genetic loci to this susceptibility. 7, 15) To examine whether expression of PTTG and its regulation by E 2 might be involved in E 2 -induced pituitary tumorigenesis, strain differences were assessed in the present study.
MATERIALS AND METHODS
Animals Female F344, SD, Donryu and Brown-Norway rats were purchased at 4 weeks of age from Charles River Japan Co. (Kanagawa). They were maintained with free access to basal diet and tap water. All animals were surgically ovariectomized upon receipt and implanted with pellets containing 10 mg of E 2 subcutaneously as described previously. 16) For the time-course study, F344 rats were treated with E 2 for 4, 8 and 13 weeks in the long term experiment (5 animals, each point), and for 12, 24, 48 and 96 h for the short term (4 animals, each point). For the comparison study among four strains, they were treated with E 2 for 72 h for the short term effects and for 4 weeks for the long term effect (5 animals, each strain and treat-ment). Animals were sacrificed under ether anesthesia. The pituitary gland and the uterus of each rat were weighed and immediately frozen in liquid nitrogen and stored at −80°C. Blood samples were collected from the abdominal artery and separated sera were stored at −20°C until assayed. All experiments were conducted under the guidelines of 'A Guide for the Care and Use of Laboratory Animals of Hiroshima University.' Total RNA extraction and reverse transcription Total RNAs were prepared from pituitary tissues with Isogen (Wakojunyaku, Osaka), a premixed RNA isolation reagent based on the acid guanidium thiocyanate-phenolchloroform extraction method, following the supplied protocol. Aliquots were treated with 1 U of RQ1 DNase (Promega, Madison, WI) in 20 µl buffer containing 10 U of RNase inhibitor, RNasin (Promega) and 1 µg of RNA was reverse-transcribed with 200 U of MMLV-RT (Life Technologies, Rockville, MD) and 50 ng of oligo-dT primer in 12 µl of buffer containing 1 mM dNTP, 100 mM Tris HCl (pH 8.3), 150 mM KCl, 6 mM MgCl 2 , 60 mM dithiothreitol and 5 U/µl RNasin with incubation at 37°C for 60 min. PCR primers rPTTG-f1 and rPTTG-r with the sequences 5′-ATGGCTACTCTGATCTTTGT (1-20) and 5′-TTAA-ATATCTGCATCGTAAC (581-600) were employed for rPTTG detection by PCR with the expected amplified size of 600 bp. For construction of the competitor, rPTTG-f2 and rPTTG-f2f1 (rPTTG-f2 linking to rPTTG-f1) with the sequences of 5′-GTTACTGAAAAGCCAGTGAA (199-218) and 5′-ATGGCTACTCTGATCTTTGTGTTAC-TGAAAAG were used. Primer sequences and conditions for G3PDH (glycerol-3-phosphate dehydrogenase) were chosen according to Weir et al. 17) (the expected size of the amplified fragment was 534 bp). Construction of competitor DNA fragments PCR amplifications were carried out with 20 pmol each of primers in a total volume of 50 µl containing 1.25 U of Ex-Taq DNase polymerase (TaKaRa Shuzo Co., Otsu), 0.2 mM dNTP and the supplied buffer. Each amplification was performed with 30 cycles at 94°C for 30 s, 55°C for 1 min and 72°C for 1 min, ending with 72°C for 5 min. PCR products were purified with agarose gel electrophoresis followed by cleaning with a GFX Gel Band Purification Kit (Amersham Pharmacia Biotech, Uppsala, Sweden). First, a 600 bp fragment was amplified by PCR with rPTTG-f1 and rPTTG-r from rat pituitary tumor cDNA. The DNA sequence was confirmed with an ABI PRISM 310 capillary sequencer (Applied Biosystems, Foster City, CA). Using this fragment as a template, the next PCR amplification with primers rPTTG-f2 and rPTTG-r was performed and the resulting 401 bp PCR fragment was gel-purified. Then the third PCR amplification was carried out from the 401 bp fragment with rPTTG-f1f2 and rPTTG-r to obtain a 421 bp competitor DNA for rPTTG.
Competitive PCR Sample cDNA (equivalent to 0.2 µg of total RNA) and various amounts (0-15 fg) of competitor DNA were co-amplified by PCR with Ex-Taq using the rPTTG-f1 and rPTTG-r primer set. The amplification conditions were as described above in a final volume of 20 µl. Each PCR product was electrophoretically separated on a 1.5% agarose gel containing ethidium bromide at 0.2 µg/ ml. The image was digitized with a video capturing device, PrintGraph (Atto Co., Tokyo) and intensities of the blots were quantified using Scion Image software (Scion Corp., Frederick, MD). The log ratio of the blot intensities of sample cDNA over the competitor in each lane was plotted against amounts of the competitor. Quantity of rPTTG mRNAs was determined where the ratio was equal to 1.
18)
Prolactin (PRL) radioimmunoassay Serum PRL was measured by radioimmunoassay with NIADDK reagents following the recommended protocol, the details of which have been reported previously. 19) E 2 radioimmunoassay Serum E 2 was measured with a radioimmunoassay kit for rat serum E 2 , purchased from Immunotech, Inc. (Marseille, Cedex, France). Statistical analysis Statistical comparisons were made using Student's t test.
RESULTS
Increase in pituitary weight and PTTG mRNA expression due to E 2 in ovariectomized female F344 rats Significant increases in pituitary weight were noted one week after the implantation of a high-dose E 2 pellet. The increase continued linearly for 13 weeks. RT-PCR detection of PTTG mRNA indicated elevated expression of the gene in the pituitary tumor induced by E 2 (Fig. 1 ). Strain differences in E 2 -induced pituitary weight increase Absolute weights of the pituitary gland varied among the four different strains. In 5-week-old control groups, the smallest size of 4.4±0.2 mg was noted in Brown-Norway rats, while the average size was 13.0 mg in the Wistar strain. Four-week treatment with E 2 increased pituitary weights in a strain-dependent manner (Table I ). The pituitary glands of F344 rats showed the highest sensitivity to E 2 in terms of weight increase. On the other hand, no weight increase in the gland was noted in Donryu rats. There were no differences in serum E 2 levels among the four strains of estrogenized rats, while the hormone was undetectable in ovariectomized animals. PTTG mRNA levels in different strains of estrogenized rats Data for PTTG mRNA levels quantified by competitive RT-PCR in ovariectomized and estrogenized rats of the four different strains are summarized in Table II . The PTTG levels in ovariectomized rats varied among the strains. When the rats were treated with E 2 for 4 weeks, the level was significantly increased only in F344 rats.
Early increase in PTTG mRNA in the pituitary gland in estrogenized F344 rats Semi-quantitative RT-PCR indicated PTTG mRNA to be significantly increased 48 h after implantation of a pellet containing 10 mg of E 2 (Fig.  2) . Measurement confirmed rapid increase in serum E 2 despite the s.c. administration route as a pellet. Early changes in uterus weights and serum PRL levels in response to E 2 Significant increases in uterus weights were noted in estrogenized groups of all of the strains at 72 h after E 2 administration. PRL levels, however, differed among strains, increasing sharply in the F344 and Wistar cases, but not significantly changing in Donryu rats (Table  III) . Early changes in PTTG mRNA due to E 2 in the four strains of rats Data for PTTG mRNA levels in the different strains of rat treated with E 2 in pellets for three days, quantified by the competitive RT-PCR technique, are sum- a) Animals were ovariectomized at 4 weeks of age and a pellet containing 10 mg of E 2 was given when they were 5 weeks old. b) Mean±SEM (n=5). * * Significant difference from the respective ovariectomized group value (P<0.01).
marized in Table IV . Significant induction of mRNA of PTTG was noted in F344 and Wistar rats.
DISCUSSION
In the rat, chronic treatment with E 2 is known to induce anterior pituitary hyperplasia and results in tumors which are initially benign and hormone-dependent, but may subsequently become autonomous. The effects of the hormone, however, vary greatly among rat strains. 7, 8) Our data clearly demonstrated PTTG in the pituitary gland to be regulated by E 2 differently in each stain, with possible involvement in the strain differences in E 2 -induced tumorigenesis. 3.0±1.0 1.1 a) Animals were ovariectomized at 4 weeks of age and a pellet containing 10 mg of E 2 was given when they were 5 weeks old. b) Mean±SEM (n=5). * * Significant difference from the respective ovariectomized group value (P<0.01). A.
B. PTTG was first isolated in rat growth hormone-secreting pituitary cell lines by the mRNA differential display method. 1, 3) Two pituitary tumor-specific mRNAs were found to be overexpressed; one was the insulin-induced growth response protein and the other was the new gene, PTTG, with a cDNA encoding a 199-amino-acid, 25-kDa protein. Northern analysis in normal adult rats indicated that only testis contained significant amounts of PTTG mRNA, which was a truncated mRNA of approximately 1 kb in contrast to the 1.3 kb mRNA expressed in pituitary tumor cells. When a fibroblast cell line, NIH3T3, was transfected with a PTTG expression vector, it exhibited colony formation, anchorage-independent growth in soft agar and development of tumors in nude mice. Subsequent investigations revealed the human homologue of PTTG to exist as a 202-amino-acid protein.
2) Human PTTG was found to be highly expressed in leukemias, lung carcinomas, lymphomas and HeLa cell lines as well as in pituitary adenomas. The protein contains both proline and basic amino acid-rich domains potentially involved in cancer-related signal transduction, and has been reported to be identical to a vertebrate sister-chromatid separation inhibitor (serurin), whose increased expression may result in genetic instability with chromosome gain or loss. 5) When pituitary tumors are induced by E 2 , clear transitions between hyperplasia, adenoma and carcinoma are not apparent despite differences in cellular atypia. The size of the pituitary gland steadily increases without any evident focal growth. It is typical for pituitary adenoma to be detected as a hemorrhagic tumor, an example being shown in Fig. 1 . The designation of tumor is given on the basis of the size of the gland and the abnormal appearance of the cells. Since the two are highly correlated, 13 ) E 2 -induced weight increase in the pituitary gland was taken to represent E 2 -responsive tumorigenicity in the present study. Satoh et al. 20) demonstrated pituitary glands to develop adenomas in all F344 rats treated with E 2 for only 7 weeks, and the adenomas progressed to carcinomas featuring local invasion or metastasis within 13 weeks after the start of hormone exposure.
Susceptibility to E 2 -induced pituitary tumor is highly strain-dependent. 7) We used four different strains which are commercially available. F344 is known to be particularly susceptible, while Donryu rats are very resistant as far as one month of E 2 treatment is concerned. Interestingly, the normal sizes of the pituitary also differ among strains, being considerably smaller in the Brown-Norway case. The determined basal levels of PTTG mRNA also varied among strains, although they did not correlate with the normal pituitary weights.
Heaney et al. 6) reported that PTTG mRNA in the pituitary gland increases early after E 2 administration in F344 rats, in accordance with our data. While a period of time necessary to induce PTTG was within 24-48 h here, being slightly longer than the 12-24 h of the previous report, the increase in PTTG was definitely prior to development of pituitary hyperplasia. Whatever the interval for initiating the transcription was, the gene might not be under direct control of E 2 . We compared PTTG induction by E 2 after 72 h in the different strains, this time point being chosen on the basis of our time-course study, and demonstrated the initial rise to be dependent on strain and correlated with susceptibility to pituitary tumorigenesis. It is well known that E 2 stimulates PRL synthesis predominantly through activation of transcription. [21] [22] [23] Serum PRL levels became extremely high in both F344 and Wistar rats when they were treated with E 2 for 72 h, while, interestingly, only a moderate increase was noted in the Brown-Norway strain and no induction in Donryu rats. However, the classical investigation by Wiklund and Gorski, 24) who compared pituitary tumor susceptibility between F344 and Holtzman strains, indicated that the lack of tumor formation in the Holtzman rat pituitary is not due to a general unresponsiveness to E 2 . They found increased DNA synthesis during the first 2-4 days of E 2 treatment and then a return to normal afterwards. On the other hand, elevation of PRL was seen as a primary response to E 2 which was sustained on prolonged E 2 treatment. This seems not to be the case in the Donryu strain which showed virtually no elevation in serum PRL level at 72 h after estrogenization in the present study. The comparison between ACI and SD rats by Stone et al., 12) however, gave findings consistent with our results, PRL induction by E 2 in ACI being much higher than that in SD rats on day 2 of diethylstilbestrol (DES) treatment. It should be pointed out that the socalled general responsiveness to E 2 in the pituitary gland has not been quantitatively assessed in a thorough manner. Serum E 2 levels were high in all four strains in the present 6.0±2.0 1.1 a) Animals were ovariectomized at 4 weeks of age and a pellet containing 10 mg of E 2 was given when they were 5 weeks old. b) Mean±SEM (n=5). * Significant difference from the respective ovariectomized group value (P<0.01).
study, indicating no difference in the E 2 metabolism. The genomic structure of rat PTTG has been characterized and at least a 745 bp 5′ flanking sequence was revealed to be required for transcriptional activation. 25) Transfection experiments with a rat PTTG-5′-flanking luciferase reporter in a rat pituitary cell line, GH3, showed that E 2 could significantly induce transcription through the promoter, albeit the effect was very weak. 6) Since there is no evidence to indicate a direct relationship between promoter sequence and E 2 receptors, activation by E 2 may be indirect, although the response clearly requires E 2 receptors according to our recent results (unpublished). Although evidence for involvement of PTTG in pituitary tumorigenesis appears to be convincing, other genes may also contribute to strain differences. Ying 26) found that p53 and rb mRNAs were increased in response to DES treatment in SD, but not in F344 rats. C-fos has also been reported to be regulated by E 2 in a specific manner in the pituitary gland of F344 rats. 
